Stock Comparison

CAPR vs VRTX

Capricor Therapeutics Inc vs Vertex Pharmaceuticals Inc

The Verdict

CAPR takes this one.

Winner

CAPR

Capricor Therapeutics Inc

8.7

out of 10

Hidden Gem

VRTX

Vertex Pharmaceuticals Inc

4.7

out of 10

Proceed with Caution

Head-to-Head

$1.2B

Market Cap

$109.0B

N/A

P/E Ratio

27.6

N/A

Profit Margin

32.9%

N/A

Return on Equity

22.7%

N/A

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate

8.7

DVR Score

4.7

The Deep Dive

CAPR8.7/10

Capricor Therapeutics is undergoing a critical transition from clinical development to commercialization following the Q3/Q4 2025 FDA approval of CAP-1002 for Duchenne Muscular Dystrophy (DMD). This approval targets a multi-billion dollar market with high unmet needs, particularly for non-ambulatory patients, offering a substantial revenue pathway. The company benefits from regulatory exclusivity ...

Full CAPR Analysis

VRTX4.7/10

Vertex Pharmaceuticals maintains its strong market position in Cystic Fibrosis and continues to advance a robust pipeline in high-growth areas like gene editing (Casgevy), non-opioid pain (VX-548), and Type 1 Diabetes. Recent FDA approval for expanded ALYFTREK use and solid Q4 2025 financials (revenue beat, strong EPS growth) underscore its operational strength and profitability. However, for a co...

Full VRTX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.